Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: Results of a phase II clinical trial

Brian C. Toy, Euna Koo, Catherine Cukras, Catherine B. Meyerle, Emily Y. Chew, Wai T. Wong

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE: To evaluate the safety and preliminary efficacy of intravitreal ranibizumab for nonneovascular idiopathic macular telangiectasia Type 2. METHODS: Single-center, open-label Phase II clinical trial enrolling five participants with bilateral nonneovascular idiopathic macular telangiectasia Type 2. Intravitreal ranibizumab (0.5 mg) was administered every 4 weeks in the study eye for 12 months with the contralateral eye observed. Outcome measures included changes in best-corrected visual acuity, area of late-phase leakage on fluorescein angiography, and retinal thickness on optical coherence tomography. RESULTS: The study treatment was well tolerated and associated with few adverse events. Change in best-corrected visual acuity at 12 months was not significantly different between treated study eyes (0.0 ± 7.5 letters) and control fellow eyes (+2.2 ± 1.9 letters). However, decreases in the area of late-phase fluorescein angiography leakage (-33 ± 20% for study eyes, +1 ± 8% for fellow eyes) and in optical coherence tomography central subfield retinal thickness (-11.7 ± 7.0% for study eyes and-2.9 ± 3.5% for fellow eyes) were greater in study eyes compared with fellow eyes. CONCLUSION: Despite significant anatomical responses to treatment, functional improvement in visual acuity was not detected. Intravitreal ranibizumab administered monthly over a time course of 12 months is unlikely to provide a general and significant benefit to patients with nonneovascular idiopathic macular telangiectasia Type 2.

Original languageEnglish (US)
Pages (from-to)996-1006
Number of pages11
JournalRetina
Volume32
Issue number5
DOIs
StatePublished - May 2012

Keywords

  • IMT2
  • anti-VEGF
  • clinical trial
  • idiopathic macular telangiectasia
  • ranibizumab

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: Results of a phase II clinical trial'. Together they form a unique fingerprint.

Cite this